Abstract
Introduction
Ovarian cancer is the most lethal gynaecological cancer with over 15,000 estimated deaths in United States in 2008 [1] . Standard treatment is primary cytoreduction followed by adjuvant platinum and taxane based chemotherapy [2] [3] [4] . An alternative therapeutic strategy under investigation is neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) and adjuvant chemotherapy [5] [6] [7] . Patients' prognosis is strictly dependent on surgical outcome [6] [7] [8] . This has lead research worldwide to propose cytoreduction also for the treatment of platinum sensitive recurrent disease (secondary cytoreduction) [9] .
There are several hypotheses that could explain the important clinical impact of cytoreductive surgery in this cancer. It is reasonable to believe that surgery is able to remove poorly vascularized tissues, decrease tumour burden and therefore allow proliferation of tumour residual cells that are more susceptible to cytotoxic drugs [8, 10, 11] . Recently, an appealing hypothesis that is emerging is that tumour debulking reduces tumour-induced immunosuppression [12] . [11, 13, 14] , deletion of tumour-reactive T cells [15] , induction of suppressive [15] . In the last decade, the fundamental role of naturally or induced Treg cells in tumour progression has been demonstrated. Treg cells are able to maintain immune tolerance, thanks to their ability to inhibit CD4 and CD8 T lymphocyte activation [16] . In women affected by epithelial ovarian malignancies, Treg are recruited primarily in neoplastic tissue and ascites [17] . The detrimental effect of Treg cells and their inhibitory activity on cytotoxic lymphocytes are well established by the strong prognostic correlation of CD8/CD4 Treg ratio [18] . Considering the numerous immunosuppressive mechanisms adopted by cancer cells, it is conceivable to believe that tumour removal could affect the immunological repertoire of cancer patients, but, currently, no clinical data are available to support this hypothesis [19] .
It is well known that neoplasms are able to induce immune tolerance through different mechanisms including the release of immune suppressive cytokines (interleukin [IL]-10, transforming growth factor [TGF]-␤1, VEGF, prostaglandin E2 [PGE2])

Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression
In this study, we analysed the effect of tumour debulking in ovarian cancer patients' immune signatures, in order to understand if immunological mechanisms might be involved in the clinical benefit associated with the achievement of primary optimal residual disease. 
Materials and methods
Patients' characteristics
Serum cytokine detection
T-cell stimulation and IFN-␥ ELISpot assay
PBMCs, derived from three pOC patients at days 0 and 15, were cocultured with HLA-A2 ϩ 
K562 cell line, pulsed with Flu peptide (GILGFVFTL, 10 mg/ml) (ProImmune, Oxford, UK) and irradiated with 30 Gy, for 12 days in presence of IL-2 (10 U/ml) and IL-15 (10 ng/ml) (R&D Systems). At day 12, CD8 T cells were purified and plated in triplicate for 24 hrs with transfected K562 cells with or without Flu peptide (50 mg/ml). Interferon (IFN)-␥ production was detected by ELISpot assay. Spots were counted using the ImmunoSpot Image Analyzer (Aelvis, Cologne, Germany).
Statistical analysis
Results
Patients' characteristics
Patients' characteristics are described in Table 1 [21] (Fig. 3) . Figure 3A shows the changes of circulating CD4 T cell after tumour removal. Before surgery, the relative proportion of 
CD4 effector T cells was significantly higher (P Ͻ 0.05) in pOC patients when compared with the control group. There was a significant increase in CD4 effector T cells after surgery (P Ͻ 0.05). Before surgery, CD4 naïve T cells were significantly lower in the pOC group as compared to controls. In the pOC
Fig. 1 Circulating CD4 Treg cell analysis in ovarian cancer patients and controls and Treg immunosuppression assay. Lymphocytes were analysed by cytofluorimetry for the expression of CD4, CD25 and FOXP3 molecules. (A) shows dot plots of CD4 and CD25 markers after gating on lymphocytes at days 0, 2 and 15 (in the square, the percentage of double positive cells). Histogram plots represent the expression of FOXP3 in CD4 ϩ
CD25 ϩ T cells with the corresponding mean fluorescence intensity (bold line and thin line corresponding to FOXP3 antigen and isotype control, respectively). Results are related to a representative pOC donor. (B) shows CD4
Circulating CD8 T cells were also analysed in order to evaluate the proportion of the different CD8 T-cell subsets (Fig. 3B). Before surgery, pOC patients had a significantly lower proportion of CD8 effector T cells and CD8 naïve T cells compared to controls, whereas CD8 central memory and effector memory T cells were significantly higher. Tumour primary debulking induced a significant increase in CD8 effector T cells (P Ͻ 0.05), while no changes were observed in the other T-cell subsets. IDS patients had a significantly lower proportion of naïve T cells and a higher level of CD8 memory and effector memory T cells than the control, but no modification occurred in all CD8 subsets after 2 weeks from surgery. Similar to what observed in the CD4 population, no significant differences in the CD8 T subsets was observed between rOC patients and the control group. CD8 T-cell population did not vary significantly after secondary debulking.
CD8/CD4 Treg ratio in tumour samples represents a significant prognostic factor [18] . pOC patients after tumour debulking had a significant increase in the ratio of circulating CD8/CD4 Treg (8.5 Ϯ 3.0 
Neoadjuvant chemotherapy decreases the percentage of circulating T reg cells
In the IDS group, the phenotype of lymphocyte populations derived from patients subjected to NACT were also evaluated at ES and compared with day 0 of pOC and IDS groups. The percentage of Treg cells before chemotherapy was similar to the one observed at day 0 in the pOC group (day 0 pOC versus ES 2.4 Ϯ 1.2 versus 2.9 Ϯ 1.3, P ϭ 0.3) (Fig. 4A) (Fig. 4B and C ). 
IL-10 serum level is reduced after primary cytoreduction
T cell capacity to respond to specific and unspecific antigens increases after primary cytoreduction
